Related Experiment Video
Updated: Mar 18, 2026
08:40
Quantitation of Protein Expression and Co-localization Using Multiplexed Immuno-histochemical Staining and Multispectral Imaging
Published on: April 8, 2016
13.5K
Immunophenotypic Characterization of Benign and Malignant Prostatic Lesions
R Lakhtakia1, R Bharadwaj2, V K Kumar3
1Senior Advisor (Pathology), Command Hospital (CC), Lucknow.
Medical Journal, Armed Forces India
|July 14, 2016
Summary
Immunophenotyping refines prostate cancer diagnosis by assessing differentiation and proliferation markers. These markers objectively evaluate tumor characteristics and growth potential, aiding in diagnosis and therapy assessment.
Area of Science:
- Uropathology
- Oncology
- Molecular Pathology
Background:
- Biopsy is the gold standard for diagnosing prostate enlargement.
- Immunophenotypic analysis can supplement traditional biopsy diagnosis.
Purpose of the Study:
- To enhance the differentiation between benign and malignant prostatic lesions.
- To supplement biopsy diagnosis using immunophenotypic markers.
Main Methods:
- Compared 25 cases each of nodular hyperplasia and adenocarcinoma.
- Utilized antibodies for prostate-specific antigen (PSA), transglutaminase, chromogranin, high molecular weight keratin (HMWK), proliferating cell nuclear antigen, apoptosis, and CD 34.
Main Results:
- Differentiation markers (PSA, transglutaminase) helped identify higher-grade tumors.
- HMWK identified loss of basal cells, aiding in diagnosing atypical lesions and prostatic intraepithelial neoplasia.
- Proliferation indices identified tumors with higher growth fractions within Gleason grades.
Conclusions:
- Immunophenotypic assessment refines the morphologic diagnosis of prostate lesions.
- Differentiation and proliferation markers objectively assess tumor biology and growth potential.
- Recommended for diagnostic use and assessing therapy response.
